Working…
COVID-19 is an emerging, rapidly evolving situation.
Get the latest public health information from CDC: https://www.coronavirus.gov.

Get the latest research information from NIH: https://www.nih.gov/coronavirus.
ClinicalTrials.gov
ClinicalTrials.gov Menu

Transcranial Magnetic Stimulation in Episodic Migraine (Magnet-EM) (Magnet-EM)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT03556722
Recruitment Status : Active, not recruiting
First Posted : June 14, 2018
Last Update Posted : October 19, 2020
Sponsor:
Information provided by (Responsible Party):
Wan Aliaa Wan Sulaiman, Universiti Putra Malaysia

Brief Summary:
This study will assess the safety and efficacy of repetitive transcranial magnetic stimulation (rTMS) as new preventive treatment of migraine.

Condition or disease Intervention/treatment Phase
Migraine Device: Repetitive Transcranial Magnetic Stimulation. Device: Sham rTMS Not Applicable

Detailed Description:
Migraine patients according to International Headache Society criteria will be allocated randomly into two treatment arms. One group will receive active rTMS and another group will receive sham rTMS for treatment phase (5 sessions). Assessment will be made at baseline, month 1, month 2 and month 3 post-treatment.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 76 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Intervention Model Description: Two-arm parallel assignment involves two groups of participants. One group receives r-TMS, and the other group receives sham placebo r-TMS.
Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
Masking Description: Double blinded
Primary Purpose: Treatment
Official Title: Effectiveness and Tolerability of Repetitive Transcranial Magnetic Stimulation For Preventive Treatment Of Episodic Migraine: A Single Centre, Randomised, Double-Blind, Sham-Controlled Phase 2 Trial
Actual Study Start Date : April 15, 2019
Estimated Primary Completion Date : January 15, 2021
Estimated Study Completion Date : January 15, 2021

Resource links provided by the National Library of Medicine

MedlinePlus Genetics related topics: Migraine
MedlinePlus related topics: Migraine

Arm Intervention/treatment
Active Comparator: repetitive Transcranial Magnetic Stimulation
Magstim Rapid-2 (Whitland, Walsh, UK), 70mm Double Air Film Coil given on left dorsolateral prefrontal cortex for five sessions.
Device: Repetitive Transcranial Magnetic Stimulation.
High frequency rTMS on left dorsolateral prefrontal cortex.
Other Name: rTMS

Sham Comparator: Sham repetitive Transcranial Magnetic Stimulation
Magstim Rapid-2 (Whitland, Walsh, UK), 70mm Double Air Film Sham Coil given on left dorsolateral prefrontal cortex for five sessions.
Device: Sham rTMS
Sham rTMS without active magnetic coil on left dorsolateral prefrontal cortex.
Other Name: Placebo




Primary Outcome Measures :
  1. Change from baseline in mean monthly migraine days. [ Time Frame: Baseline and month 1, 2 and 3 post treatment ]
    The mean monthly migraine days will be calculated using the monthly migraine days from each of the month of the double-blind treatment phase.


Secondary Outcome Measures :
  1. Change from baseline in mean monthly migraine attacks. [ Time Frame: Baseline and month 1, 2 and 3 post treatment ]
    The mean monthly migraine attacks will be calculated using the monthly migraine attack from each of the month of the double-blind treatment phase.

  2. Proportion of subjects with at least a 50% reduction from baseline in mean monthly migraine days. [ Time Frame: Baseline and month 1, 2 and 3 post treatment ]
    Change from baseline in mean monthly pain intensity of migraine attacks. The mean monthly pain intensity will be based on the record of the maximal pain intensity by means of a verbal scale (i.e. 0 =no headache; 1 = mild headache; 2 = moderate headache; 3 = severe headache) prior to taking symptomatic medication.

  3. Frequency and severity of adverse events in response to rTMS. [ Time Frame: During treatment and up until 1 month post treatment ]
    Recorded any adverse events as per Good Clinical Practice Guideline and Declaration of Helsinki.

  4. The Depression Anxiety Stress Scale (DASS 21) score changes in migraine patients in response to rTMS. [ Time Frame: Baseline and at month 3 post treatment ]
    Mean score changes from baseline for depression, anxiety and stress category.

  5. The Migraine Disability Assessment Test (MIDAS) score changes in migraine patients in response to rTMS. [ Time Frame: Baseline and at month 3 post treatment ]
    Mean score changes from baseline.

  6. The Migraine Specific Questionnaire (MSQ) version 2.1 score changes in migraine patients in response to r-TMS. [ Time Frame: Baseline and at month 3 post treatment ]
    Mean score changes from baseline.

  7. The EQ-5D score changes in migraine patients in response to rTMS. [ Time Frame: Baseline and at month 3 post treatment ]
    Mean score changes from baseline.

  8. The Pittsburgh Sleep Quality Index score changes in migraine in response to rTMS. [ Time Frame: Baseline and at month 3 post treatment ]
    Mean score changes from baseline for sleep quality.

  9. The Food Frequency Questionnaire score changes in migraine in response to rTMS. [ Time Frame: Baseline ]
    Measuring food frequency intake at baseline

  10. The Global Physical Activity Questionnaire score change in migraine in response to rTMS. [ Time Frame: Baseline and at month 3 post treatment ]
    Mean score changes from baseline.

  11. Transcranial Doppler (TCD) pattern changes in migraine patients in response to rTMS. [ Time Frame: Baseline and at month 3 post treatment ]
    Mean flow velocity (cm/s).

  12. Electroencephalography (EEG) pattern change in migraine patients in response to rTMS. [ Time Frame: Baseline and at month 3 post treatment ]
    EEG pattern differences based on report.

  13. Serum serotonin level in migraine patients in response to rTMS. [ Time Frame: Baseline and at month 3 post treatment ]
    Serum serotonin (ng/ml).

  14. Serum beta-endorphin level changes in migraine patients in response to rTMS. [ Time Frame: Baseline and at month 3 post treatment ]
    Serum beta endorphin (ng/ml).

  15. Serum Calcitonin gene related peptide (CGRP) level in migraine patients in response to rTMS. [ Time Frame: Baseline and at month 3 post treatment ]
    Serum CGRP (pg/ml).

  16. Satisfaction measures of efficacy, tolerability, safety and expectations of rTMS among the participants. [ Time Frame: At month 3 post treatment ]
    A 5-point, Likert scale will be used to evaluate satisfaction with rTMS in migraine prevention.



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years to 60 Years   (Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion criteria:

  1. Males or females aged 18 to 60 years of age.
  2. Subjects fulfilling criteria for episodic migraine as per the Third Edition of The International Headache Society (ICHD-3) for at least 1 year.
  3. Frequency of migraine attacks 2-8 times per month with less than 15 headache days per month for at least 3 months prior to screening.
  4. Demonstrated compliance with the headache diary during the run-in period by entry of headache data on a minimum of 24/30 days (80% compliance).
  5. A signed and dated informed consent document indicating that the subject has been informed of all pertinent aspects of the study including any known and potential risks and available alternative treatments.

Exclusion criteria:

  1. Patients with previous history of rTMS treatment.
  2. Onset of headache at more than 50-year-old.
  3. Headache with red flags symptoms that may suggest organic secondary headaches.
  4. Pregnant or lactating women.
  5. Patients with contraindications to TMS such as metallic implant and pacemaker based on the Screening 13-item Questionnaire for rTMS candidate.
  6. Patients with medical conditions such severe hypertension, infections, malignancy, cardiovascular and cerebrovascular disease, epilepsy degenerative central nervous system diseases, renal failure, hepatic failure, bleeding diathesis and serious mental illness.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03556722


Locations
Layout table for location information
Malaysia
University Putra Malaysia
Serdang, Selangor, Malaysia, 43400
Sponsors and Collaborators
Universiti Putra Malaysia
Investigators
Layout table for investigator information
Study Chair: Hamidon B. Basri University Putra Malaysia
Study Director: Wan Aliaa B. Wan Sulaiman, MRCP Universiti Putra Malaysia
Principal Investigator: Wan Aliaa B. Wan Sulaiman, MRCP Universiti Putra Malaysia
Layout table for additonal information
Responsible Party: Wan Aliaa Wan Sulaiman, Associate Professor, Universiti Putra Malaysia
ClinicalTrials.gov Identifier: NCT03556722    
Other Study ID Numbers: GPB/2017/9585500
First Posted: June 14, 2018    Key Record Dates
Last Update Posted: October 19, 2020
Last Verified: October 2020
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No
Keywords provided by Wan Aliaa Wan Sulaiman, Universiti Putra Malaysia:
Repetitive Transcranial Magnetic Stimulation
Transcranial Doppler
Neuromodulation
Randomized Controlled Trials
Pain
Migraine prophylaxis
Dorsolateral Prefrontal Cortex
Protocol
Additional relevant MeSH terms:
Layout table for MeSH terms
Migraine Disorders
Headache Disorders, Primary
Headache Disorders
Brain Diseases
Central Nervous System Diseases
Nervous System Diseases